GOSS
Gossamer Bio, Inc.
Healthcare — Biotechnology
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $81.98M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.82 |
| EPS (TTM) | $-0.79 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 71.50% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Hold 2.7 |
| Analyst Target | $3.86 |
| Analysts | 5 |
| Next Earnings | May 18, 2026 |
| Indexes | - |
Technical Indicators
| RSI (14) | 56.0 |
| Beta | 2.01 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.87 |
| 52-Week Low | $0.14 |
| 50-Day Avg | $0.25 |
| 200-Day Avg | $1.66 |
| Avg Volume | $12.03M |
| Volume | $11.30M |
Performance Analysis
NEUTRALGOSS presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:12 UTC
Back to Screener Export Report